eMedicine Specialties > Infectious Diseases > Mycobacterial Infections

Mycobacterium Haemophilum: Follow-up

Author: Natalie C Klein, MD, PhD, Associate Professor, Department of Medicine, Division of Infectious Diseases, SUNY School of Medicine at Stony Brook; Associate Director, Winthrop-University Hospital
Contributor Information and Disclosures

Updated: Nov 20, 2007

Follow-up

Further Inpatient Care

  • M haemophilum infection is diagnosed in many immunosuppressed patients who are hospitalized.
  • Treatment can be started or continued on an outpatient basis in most patients.

Further Outpatient Care

  • Patients require close outpatient follow-up care to document response to therapy (eg, every 2-4 wk). Length of therapy is prolonged in immunosuppressed patients, and patients with irreversible immunosuppression may require life-long suppressive therapy. Relapses have occurred in patients with AIDS who were on suppressive therapy. Whether patients on highly active antiretroviral therapy (HAART) can stop therapy if they have a good HAART response is unknown.
  • Discuss adherence to medications extensively with the patient to avoid development of resistance.

Prognosis

  • Prognosis for children with localized lymphadenitis is good.
  • In adults, the outcome is determined by their immune function.
  • In severely immunosuppressed patients, disease may require long-term therapy. Despite maintenance therapy, infection may persist or recur.

Patient Education

  • Adherence to medication is of utmost importance to prevent resistance.
  • Instruct patients to list all medications to avoid drug interactions.
  • Rifampin and rifabutin may interfere with contraceptives and numerous other medications, especially HIV-related therapy.

Miscellaneous

Medicolegal Pitfalls

  • Rifampin and rifabutin may interfere with contraceptives; the patient may become pregnant.
  • Ciprofloxacin, but not other quinolones, rarely cause Achilles tendon ruptures; avoid high-impact sports.
 


More on Mycobacterium Haemophilum

Overview: Mycobacterium Haemophilum
Differential Diagnoses & Workup: Mycobacterium Haemophilum
Treatment & Medication: Mycobacterium Haemophilum
Follow-up: Mycobacterium Haemophilum
References
[ CLOSE WINDOW ]

References

  1. Lindeboom JA, Kuijper CF, van Furth M. Inguinal lymphadenitis caused by mycobacterium haemophilum in an immunocompetent child. Pediatr Infect Dis J. Jan 2007;26(1):84-6. [Medline].

  2. Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Prins JM. First case of an oculofacial lesion due to Mycobacterium haemophilum infection in an immunocompetent child. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Jun 2006;101(6):774-6. [Medline].

  3. Kiehn TE, White M. Mycobacterium haemophilum: an emerging pathogen. Eur J Clin Microbiol Infect Dis. Nov 1994;13(11):925-31. [Medline].

  4. Sturenburg EE, Horstkotte MA, Aberle J, Meyer K, Richter E, Laufs R, et al. Disseminated Mycobacterium haemophilum infection as initial manifestation of AIDS. Tuberculosis (Edinb). 2004;84(6):341-5. [Medline].

  5. White MH, Papadopoulos EB, Small TN, Kiehn TE, Armstrong D. Mycobacterium haemophilum infections in bone marrow transplant recipients. Transplantation. Nov 15 1995;60(9):957-60. [Medline].

  6. Ward MS, Lam KV, Cannell PK, Herrmann RP. Mycobacterial central venous catheter tunnel infection: a difficult problem. Bone Marrow Transplant. Aug 1999;24(3):325-9. [Medline].

  7. Smith S, Taylor GD, Fanning EA. Chronic cutaneous Mycobacterium haemophilum infection acquired from coral injury. Clin Infect Dis. Oct 1 2003;37(7):e100-1. [Medline].

  8. Shih JY, Hsueh PR, Chang YL, Lin SF, Teng LJ, Luh KT. Pyomyositis due to Mycobacterium haemophilum in a patient with polymyositis and long-term steroid use. Clin Infect Dis. Feb 1998;26(2):505-7. [Medline].

  9. Abbott MR, Smith DD. The pathogenic effects of Mycobacterium haemophilum in immunosuppressed albino mice. J Med Microbiol. Nov 1980;13(4):535-40. [Medline].

  10. Wang SX, Sng LH, Leong HN, Tan BH. Direct identification of Mycobacterium haemophilum in skin lesions of immunocompromised patients by PCR-restriction endonuclease analysis. J Clin Microbiol. Jul 2004;42(7):3336-8. [Medline].

  11. Bruijnesteijn van Coppenraet LE, Kuijper EJ, Lindeboom JA, Prins JM, Claas EC. Mycobacterium haemophilum and lymphadenitis in children. Emerg Infect Dis. Jan 2005;11(1):62-8. [Medline].

  12. Lindeboom JA, Kuijper EJ, Prins JM, Bruijnesteijn van Coppenraet ES, Lindeboom R. Tuberculin skin testing is useful in the screening for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis. Dec 15 2006;43(12):1547-51. [Medline].

  13. Armstrong D, Kiehn T, Boone MW. From the Centers for Disease Control. Mycobacterium haemophilum infections--New York City metropolitan area, 1990-1991. JAMA. Jan 8 1992;267(2):215-6. [Medline].

  14. Dever LL, Martin JW, Seaworth B, Jorgensen JH. Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS. Clin Infect Dis. Jun 1992;14(6):1195-200. [Medline].

  15. Elsayed S, Read R. Mycobacterium haemophilum osteomyelitis: case report and review of the literature. BMC Infect Dis. 2006;6:70. [Medline].

  16. Holladay KL, Carmichael JK. Mycobacterium haemophilum cellulitis and osteomyelitis in a man with AIDS. J Am Board Fam Pract. Mar-Apr 1996;9(2):122-4. [Medline].

  17. Lefkowitz RA, Singson RD. Considering Mycobacterium haemophilum in the differential diagnosis for lytic bone lesions in AIDS patients who present with ulcerating skin lesions. Skeletal Radiol. Jun 1998;27(6):334-6. [Medline].

  18. Lin JH, Chen W, Lee JY, Yan JJ, Huang JJ. Disseminated cutaneous Mycobacterium haemophilum infection with severe hypercalcaemia in a failed renal transplant recipient. Br J Dermatol. Jul 2003;149(1):200-2. [Medline].

  19. Plemmons RM, McAllister CK, Garces MC, Ward RL. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. Clin Infect Dis. May 1997;24(5):995-7. [Medline].

  20. Samra Z, Kaufmann L, Zeharia A, Ashkenazi S, Amir J, Bahar J, et al. Optimal detection and identification of Mycobacterium haemophilum in specimens from pediatric patients with cervical lymphadenopathy. J Clin Microbiol. Mar 1999;37(3):832-4. [Medline].

  21. Saubolle MA, Kiehn TE, White MH, Rudinsky MF, Armstrong D. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev. Oct 1996;9(4):435-47. [Medline].

  22. Straus WL, Ostroff SM, Jernigan DB, Kiehn TE, Sordillo EM, Armstrong D, et al. Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients. Ann Intern Med. Jan 15 1994;120(2):118-25. [Medline].

  23. Tan HH, Tan A, Theng C, Ng SK. Cutaneous Mycobacterium haemophilum infections in immunocompromised patients in a dermatology clinic in Singapore. Ann Acad Med Singapore. Jul 2004;33(4):532-6. [Medline].

  24. van Coppenraet LS, Smit VT, Templeton KE, Claas EC, Kuijper EJ. Application of real-time PCR to recognize atypical mycobacteria in archival skin biopsies: high prevalence of Mycobacterium haemophilum. Diagn Mol Pathol. Jun 2007;16(2):81-6. [Medline].

  25. White DA, Kiehn TE, Bondoc AY, Massarella SA. Pulmonary nodule due to Mycobacterium haemophilum in an immunocompetent host. Am J Respir Crit Care Med. Oct 1999;160(4):1366-8. [Medline].

  26. Yarrish RL, Shay W, LaBombardi VJ, Meyerson M, Miller DK, Larone D. Osteomyelitis caused by Mycobacterium haemophilum: successful therapy in two patients with AIDS. AIDS. Jun 1992;6(6):557-61. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

M haemophilum, Hodgkin disease, Hodgkin's disease, septic arthritis, osteomyelitis, pulmonary infection, mycobacteremia, Mycobacterium haemophilum infection, M haemophilum infection, cervical lymphadenopathy, lymphadenitis, pneumonia, central venous catheter tunnel infection, chronic cutaneous granulomata

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Natalie C Klein, MD, PhD, Associate Professor, Department of Medicine, Division of Infectious Diseases, SUNY School of Medicine at Stony Brook; Associate Director, Winthrop-University Hospital
Natalie C Klein, MD, PhD is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and New York County Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Klaus-Dieter Lessnau, MD, FCCP, Clinical Assistant Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory, Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital
Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Artificial Internal Organs, American Thoracic Society, Physicians for Social Responsibility, and Society of Critical Care Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Aaron Glatt, MD, Professor of Clinical Medicine, New York Medical College; Chief Medical Officer, Departments of Medicine and Infectious Diseases, New Island Hospital
Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, and Society for Healthcare Epidemiology of America
Disclosure: Nothing to disclose.

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.